EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083

Todd T Brown iD, Robert F Arao, Maryam Warsi, Nittaya Phanuphak, Ricardo Vasconcelos iD, Temitope Oyedele, Philip A Sullivan, Brett Hanscom iD, James F Rooney, Alex R Rinehart, Marybeth McCauley, Beatriz Grinsztejn und 1 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf221 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Todd T Brown und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents, Tenofovir. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a randomized clinical trial, pre-exposure prophylaxis (PrEP) with long-acting cabotegravir (CAB-LA) had a better bone safety profile than tenofovir disoproxil fumarate–emtricitabine (TDF-FTC) over 105 weeks. For individuals with low bone mineral density or other fracture risk factors, CAB-LA PrEP should be considered over TDF-based PrEP. Clinical Trials Registration. clinicaltrials.gov (NCT02720094).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisAnti-HIV AgentsTenofovirEmtricitabinePyridonesEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHumansFemaleMaleTransgender PersonsAdultBone DensityMiddle AgedYoung AdultDiketopiperazines

Stichwörter der Autor:innen

HIV pre-exposure prophylaxisbone mineral densitycabotegravirtenofovir disoproxil fumarate

Substanzen

Anti-HIV AgentsTenofovircabotegravirEmtricitabinePyridonesEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationDiketopiperazines

Autor:innen und Institutionen

  • Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Institute of HIV Research and Innovation, Bangkok, Thailand.
  • Department of Infectious and Parasitic Diseases, University of Sao Paulo, Sao Paolo, Brazil.
  • Astra Zeneca, Gaithersburg, Maryland, USA.
  • Gilead Sciences, Foster City, California, USA.

ORCID-Profile: Todd T Brown, Ricardo Vasconcelos, Brett Hanscom, Raphael J Landovitz

Förderung

  • NIAID NIH HHS

Zitieren

APA

Brown, T. T., Arao, R. F., Warsi, M., Phanuphak, N., Vasconcelos, R., Oyedele, T., Sullivan, P. A., Hanscom, B., Rooney, J. F., Rinehart, A. R., McCauley, M., Grinsztejn, B., & Landovitz, R. J. (2025). Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf221

Vancouver

Brown TT, Arao RF, Warsi M, Phanuphak N, Vasconcelos R, Oyedele T, et al. Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf221

BibTeX
@article{Brown2025,
  author = {Brown, Todd T and Arao, Robert F and Warsi, Maryam and Phanuphak, Nittaya and Vasconcelos, Ricardo and Oyedele, Temitope and Sullivan, Philip A and Hanscom, Brett and Rooney, James F and Rinehart, Alex R and McCauley, Marybeth and Grinsztejn, Beatriz and Landovitz, Raphael J},
  title = {Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf221}
}
Kostenlos starten →